Aktis Oncology Analyst Price Targets

Wall Street analyst price targets and consensus rating for Aktis Oncology (AKTS).

Price Target Range — 5 Quarters

Analyst Consensus — 9 Analysts

1S.Buy

7Buy

1Hold

Consensus RatingOutperform# Analysts9Avg. Consensus PT$32Upside to Avg. PT+97.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 2, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$35
Sep 9, 2026	Oppenheimer	Jeff Jones	Initiate	Outperform	$40
Aug 19, 2026	Wedbush	David Nierengarten	Initiate	Outperform	$35
Aug 19, 2026	BMO Capital	David Lebowitz	Initiate	Outperform	$37
Jul 14, 2026	JP Morgan	Jessica Fye	PT Raise	Overweight	$30→$33
Jun 16, 2026	Raymond James	Christopher Raymond	Initiate	Strong Buy	$40
Jun 2, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$33→$35
Apr 29, 2026	William Blair	Alexandra Ramsey	Initiate	Outperform	—
Mar 31, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$30→$33
Mar 9, 2026	HC Wainwright & Co.	Robert Burns	Initiate	Buy	$30
Feb 3, 2026	Leerink Partners	—	Initiate	Outperform	$31
Feb 3, 2026	JP Morgan	Jessica Fye	Initiate	Overweight	$30
Jan 4, 2024	Piper Sandler	Harsh Kumar	Downgrade	Overweight→Neutral	$2→$1

Analyst Ratings News

PRO
Wedbush Reiterates Outperform on Aktis Oncology, Maintains $35 Price Target

Wedbush analyst David Nierengarten reiterates Aktis Oncology (NASDAQ:AKTS) with a Outperform and maintains $35 price target.

Benzinga Newsdesk

PRO
Oppenheimer Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $40

Oppenheimer analyst Jeff Jones initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $40.

Benzinga Newsdesk

PRO
Wedbush Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $35

Wedbush analyst David Nierengarten initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $35.

Benzinga Newsdesk

PRO
BMO Capital Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $37

BMO Capital analyst David Lebowitz initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $37.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Aktis Oncology, Raises Price Target to $33

JP Morgan analyst Jessica Fye maintains Aktis Oncology (NASDAQ:AKTS) with a Overweight and raises the price target from $30 to $33.

Benzinga Newsdesk

This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday

Top Wall Street analysts changed outlook on top names. For all changes, including upgrades/downgrades, visit analyst ratings page. Consider buying AKTS stock? Analysts weigh in.

Avi Kapoor

Aktis Oncology Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Aktis Oncology Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Wedbush Reiterates Outperform on Aktis Oncology, Maintains $35 Price Target

PRO
Oppenheimer Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $40

PRO
Wedbush Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $35

PRO
BMO Capital Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $37

PRO
JP Morgan Maintains Overweight on Aktis Oncology, Raises Price Target to $33

This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday

People Also Watch

People Also Watch

Aktis Oncology Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Aktis Oncology Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWedbush Reiterates Outperform on Aktis Oncology, Maintains $35 Price Target

PROOppenheimer Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $40

PROWedbush Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $35

PROBMO Capital Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $37

PROJP Morgan Maintains Overweight on Aktis Oncology, Raises Price Target to $33

This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday

People Also Watch

People Also Watch

PRO
Wedbush Reiterates Outperform on Aktis Oncology, Maintains $35 Price Target

PRO
Oppenheimer Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $40

PRO
Wedbush Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $35

PRO
BMO Capital Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $37

PRO
JP Morgan Maintains Overweight on Aktis Oncology, Raises Price Target to $33